• Animal Bioscience
• /
• 제36권4호
• /
• pp.591-600
• /
• 2023

Objective: We aimed to evaluate the efficacy of a modified Double-Ovsynch protocol vs artificial insemination following estrus detection (AIED) for the enhancement of reproductive performance in Hanwoo cattle. Methods: Four hundred twelve Hanwoo cows were allocated to two treatment groups. The first group of cows were administered gonadotropin releasing hormone (GnRH) on Day 36 (±0.6), prostaglandin F_2α (PGF_2α) on Day 46 (8 to 12 days later), and GnRH on Day 49, which was followed by Ovsynch, consisting of an injection of GnRH on Day 56, PGF_2α on Day 63, and GnRH 56 h and timed AI (TAI) 16 h later (modified Double-Ovsynch group, n = 203). The second group of cows underwent AIED (AIED group, n = 209) and were designated as controls. Results: The pregnancy per AI 60 days after the first AI was higher in the modified Double-Ovsynch (68.5%) than in the AIED (56.5%) group, resulting in a higher probability of pregnancy per AI (odds ratio: 1.68, p<0.05). Moreover, cows in the modified Double-Ovsynch group were more likely (hazard ratio: 1.28, p<0.05) to be pregnant by 150 days after calving than cows in the AIED group, and this difference was associated with a lower mean number of AIs per conception (1.27 vs 1.39, p<0.05) and a shorter median interval between calving and pregnancy (72 vs 78 days, p<0.1). Conclusion: The modified Double-Ovsynch protocol, adjusted according to the herd visit schedule, can be readily used to increase the pregnancy per AI following the first AI and to shorten the interval between calving and pregnancy in beef herds.

• Clinical and Experimental Reproductive Medicine
• /
• 제21권1호
• /
• pp.43-48
• /
• 1994

To evaluate the effectiveness of GnRH agonist for the treatment of uterine myoma as a cause of infertility, fourteen women were recruited to the study. The patients were treated with a delayed-release formulation of D-$Trp^6$-LHRH in biodegradable microcapsules(Decapeptyl-CR), administered intramuscularly at four week intervals for a period of six monthes. The first injection was given on day 21 of the cycle. Serum estradiol levels fell significantly to the mean value of 257.7pgjml 4 weeks after the first injection. Eleven patients in fourteen treated patients had a reduction in the size of uterine myoma as assessed by ultrasonography, two patients had no change of size and one patient had a increase of size. After the first or second injection, all patients became amenorrheic, then resumption of menstruation ocurred at 12 to 14 weeks after the last injection. Common side effects were hot flush, sweating and dyspareunia, whitch were acceptale. In Eleven patients who had a reduction in the size of uterine myoma by treatment with a delayed- release formulation of D-$Trp^6$-LHRH(Decapeptyl-CR), after above treatment with GnRH agonist, then four patients were treated with myomectomy, three patients had pregnancy and full term delivered by Cesarean section. These data suggest that administration of a delayed-release formulation of a GnRH agonist can be a worthwhile and convenient approach to the medical treatment of uterine myoma as a cause of infertility.

• 대한한의학회지
• /
• 제36권4호
• /
• pp.150-155
• /
• 2015

The purpose of this report is to evaluate effect of Korean medical treatment on idiopathic gonadotropin-dependent precocious puberty (G-DPP) patient received herbal medicine. We administered Aesopjiyoun-tang remedy to idiopathic G-DPP and analyzed the delay effect by hormonal value and radiographs; the height growth effect by measurement of height. After Korean medical treatment, suppression effect to peak-Luteinizing Hormone level (LHL) is 14.39IU/L to 10.9IU/L for 13month, growth effect to height value is 11cm/13month; and change of mean growth velocity (MGV) is 6.08cm/year to 10.06cm/year. The gain in height by treatment is 3.98cm/year. The result suggests Aesopjiyoun-tang can be an effective treatment for G-DPP. Herbal medicine can be used as an alternative treatment in place of the GnRH treatment.

• 대한한방소아과학회지
• /
• 제36권3호
• /
• pp.1-18
• /
• 2022

Objectives The purpose of this study was to investigate the current status of interventional clinical trial registration for children with precocious puberty and to secure basic data for the design of clinical trials for traditional Korean medicine treatment of precocious puberty. Methods The following resources were used to search for data: Clinicaltrial.gov, World Health Organization International Clinical Trials Registry Platform (WHO ICTRP), and Clinical Research Information Service (CRIS), using the search terms, 'Precocious puberty', 'child'. All clinical trials which were registered as of June 2022 were used. Results For the intervention and clinical trial design, gonadotropin releasing hormone (GnRH) analog was reported in 41.7% of trials, and single group assignment was performed in 66.7% of the studies. Prior consent had not been reported in 50% of the studies. Tanner stage and GnRH stimulation tests were reported by multiple trials as inclusion criteria, and prior treatment experiences for trial drugs were reported as exclusion criteria. The peak serum concentration of luteinizing hormone following GnRH stimulation test was used as a primary outcome in 45.8% of clinical trials, and other growth-related indicators such as growth rate, height, and predicted adult height were also reported. Conclusions In consideration of the design, eligibility criteria, and outcome measurement of the existing clinical trials identified in this study, it should be referred to in the design of clinical trials for traditional Korean medicine treatment of precocious puberty.

• 한국발생생물학회지:발생과생식
• /
• 제17권3호
• /
• pp.207-213
• /
• 2013

This study was performed to investigate the effect of peroxisome proliferators activated receptor-${\gamma}$ (PPAR-${\gamma}$) ligand, pioglitazone, on production of regulated upon activation normal T-cell expressed and secreted (RANTES) and in vitro fertilization (IVF) outcome in infertile patients with endometriosis. Sixty-four infertile patients with stage III or IV endometriosis undergoing IVF were randomly allocated to the study or the control group. The long protocol of GnRH agonist (GnRH-a) was used for controlled ovarian stimulation (COS) in all patients. Patients in the study group were treated with pioglitazone at a dose of 15 mg/day orally from the starting day of GnRH-a treatment to the day of hCG injection. Blood samples were drawn for serologic assay of RANTES on the first day of GnRH-a treatment and the day of hCG injection. There were no differences between the study and control groups in patient characteristics. There were also no differences between the two groups in COS duration, and the numbers of retrieved oocytes, fertilized oocytes and embryos transferred. The clinical pregnancy rate per cycle was higher in the study group, but this difference was not statistically significant. However, embryo implantation rate was significantly higher in the study group of 12.5% compared with 8.6% in the control group (P<0.05). The serum RANTES levels after pioglitazone treatment were significantly lower than those before pioglitazone treatmen in the study group (P<0.05). Our data suggest that pioglitazone treatment can suppress RANTES production and improve the embryo implantation rate in patients with endometriosis undergoing IVF.

• Clinical and Experimental Reproductive Medicine
• /
• 제42권2호
• /
• pp.62-66
• /
• 2015

Objective: To evaluate the effect of a gonadotropin-releasing hormone (GnRH) antagonist protocol using corifollitropin alfa in women undergoing assisted reproduction. Methods: Six hundred and eighty-six in vitro fertilization-embryo transfer (IVF)/ intracytoplasmic sperm injection (ICSI) cycles were analyzed. In 113 cycles, folliculogenesis was induced with corifollitropin alfa and recombinant follicle stimulating hormone (rFSH), and premature luteinizing hormone (LH) surges were prevented with a GnRH antagonist. In the control group (573 cycles), premature LH surges were prevented with GnRH agonist injection from the midluteal phase of the preceding cycle, and ovarian stimulation was started with rFSH. The treatment duration, quality of oocytes and embryos, number of embryo transfer (ET) cancelled cycles, risk of ovarian hyperstimulation syndrome (OHSS), and the chemical pregnancy rate were evaluated in the two ovarian stimulation protocols. Results: There were no significant differences in age and infertility factors between treatment groups. The treatment duration was shorter in the corifollitropin alfa group than in the control group. Although not statistically significant, the mean numbers of matured (86.8% vs. 85.1%) and fertilized oocytes (84.2% vs. 83.1%), good embryos (62.4% vs. 60.3%), and chemical pregnancy rates (47.2% vs. 46.8%) were slightly higher in the corifollitropin alfa group than in the control group. In contrast, rates of ET cancelled cycles and the OHSS risk were slightly lower in the corifollitropin alfa group (6.2% and 2.7%) than in the control group (8.2% and 3.5%), although these differences were also not statistically significant. Conclusion: Although no significant differences were observed, the use of corifollitropin alfa seems to offer some advantages to patients because of its short treatment duration, safety, lower ET cancellation rate and reduced risk of OHSS.

• Reproductive and Developmental Biology
• /
• 제41권2호
• /
• pp.25-31
• /
• 2017

Effective estrus detection and artificial insemination (AI) are necessary for profitable management of dairy herd. In current study, 45 crossbred lactating cows have been selected with the complaint of unobserved oestrus for more than sixty days postpartum. All cows had functional corpus luteum as examined by transrectal ultrasonography. Cows were treated with $PGF_2{\alpha}$ analogue and AI was performed with observed oestrus and then single dose of GnRH was administered. Similar synchronization protocol has been repeated after 14 days in cows that did not repose to first treatment. Remaining cows received additional $PGF_2{\alpha}$ after 14 days of second treatment and timed AI was performed following GnRH administration. Among 45 cows, 28.89% showed estrus after first treatment and 78.79% responded to second hormonal intervention. A higher conception rate (88.89% vs 26.66 and 72.72%) was observed in cows after triple administration of $PGF_2{\alpha}$ and timed AI. We noticed a significant differences in body condition score (BCS, 1~5 scale), postpartum period, and daily milk production between cows that either responded of non-responded following first and second hormonal treatment. In addition, there was a significant positive correlation between daily milk production and BCS, age and postpartum days, milk production and estrus/BCS, and milk production/BCS/estrus and conception rate. Depending upon the findings we conclude that hormonal intervention with $PGF_2{\alpha}$ and GnRH enhances postpartum ovarian cyclicity and help decreasing the days open of dairy herd. Therefore, this finding might provide an excellent guideline for target breeding system for profitable dairy herd management.

• Clinical and Experimental Pediatrics
• /
• 제49권5호
• /
• pp.552-557
• /
• 2006

목 적 : 최근 성조숙증에서 사춘기를 중단시킴으로써 성인신장을 증가시킬 수 있으리라는 기대로 조기 사춘기로 인하여 신장에 대한 예후가 불량한 소아에서 성선자극호르몬 방출호르몬 효능약제의 시도가 이루어졌다. 이에 저자들은 조기 사춘기로 예측 성인신장이 저하된 여아에서 이 약제의 신장 증가효과를 분석하고자 하였다. 방 법 : 소아과 외래에 조기 사춘기와 예측성인신장이 저신장으로 예측되는 36명의 여아를 대상으로 GnRHa를 6개월 이상 사용한 제 1군과 6개월 미만 사용한 제 2군으로 나누어 치료 시작시와 치료 후의 역연령, 골연령, 신장 및 표준편차치, 예측성 인신장 및 표준편차치, 표적키 및 표준편차치, 혈청 IGF-1, IGFBP-3 치를 비교하였다. 결 과 : 1군의 평균 치료기간은 $1.37{\pm}0.92$년, 2군은 $0.41{\pm}0.08$년이었고, 전체적으로는 $0.89{\pm}0.81$년이었다. 치료 시작시 두군 간에 역연령, 골연령, 신장, 표적키, 예측성인신장, 혈청 IGF-1 및 IGFBP-3 치의 차이는 없었고, 마지막 추적시 두 군간에 역연령, 골연령, 신장, 예측성인신장, 혈청 IGF-1 및 IGFBP-3치의 차이도 없었다. 두 군 사이에 성장속도와 치료기간에 따른 예측성인신장의 증가분은 2군이 의미 있게 높았다. 이는 2군이 치료기간이 짧아 사춘기의 성장속도가 충분히 억제되지 않은 결과로 보인다. 치료 시작시에 비하여 마지막 추적시의 예측성인신장은 의미 있게 증가하여 단기간의 치료에도 어느 정도의 효과($3.7{\pm}3.2cm$)는 있었다. 전체 대상아에서 표적키($157.3{\pm}3.1cm$)와 치료 시작시 예측성인신장($148.5{\pm}5.8cm$) 사이에는 의미있는 차이가 있었으며, 마지막 추적시의 예측성인신장($152.2{\pm}5.9cm$) 사이에도 의미 있는 차이가 있었다. 검사 소견에서 혈청 IGF-1과 IGFBP-3는 치료 시작시에 비하여 마지막 추적시에는 의미 있게 감소하여 GnRHa의 사용으로 성장호르몬-IGF 축이 다소간 억제되는 것으로 보인다. 결 론 : 사춘기가 조기에 시작하여 골연령이 역연령에 비하여 증가되어 예측성인신장이 표적키에 못 미치는 경우에 단기간의 GnRHa의 사용으로 예측성인신장은 다소 증가하였으나 표적키에는 미치지 못함을 알 수 있었으며, 성장호르몬-IGF 축의 억제가 동반되는 점에서 GnRHa 치료시 예측성인신장이 표적키에 이르기 위해서는 성장호르몬의 동시 사용이 필요하겠다.

• 한국발생생물학회지:발생과생식
• /
• 제11권1호
• /
• pp.49-54
• /
• 2007

Ethane 1,2-dimethane sulfonate(EDS)은 Leydig cells(LC)만을 선별적 사멸을 유도하는 약물로서 가역적인 테스토스테론(testosterone, T) 결핍 흰쥐 모델을 만드는데 널리 사용된다. 본 연구에서는 수컷 흰쥐 뇌하수체의 생식소자극호르몬인 LH와 FSH의 발현에 미치는 EDS 투여 효과를 조사하였다. 성숙한 수컷 흰쥐(SD strain, $300{\sim}350\;g$ B.W.)에 EDS(75 mg/kg, i.p.)를 1회 복강주사하고 주사 후 0, 1, 2, 3, 4, 5, 6 그리고 7주가 경과한 날 희생시켰다. 뇌하수체로부터 total RNA를 추출한 후 뇌하수체 glycoprotein hormone common alpha subunit($C{\alpha}$), LH beta subunit($LH{\beta}$), FSH beta subunit($FSH{\beta}$) 그리고 GnRH 수용체(GnRH-R)의 발현 변화를 semi-quantitative RT-PCR로 측정하였다. 그 결과, $C{\alpha}$ 전사수준은 주사 후 1주부터 급격히 상승하여 주사 후 4주까지 유의하게 높게 유지되다가 5주 후부터 control 수준으로 회귀하였다. $LH{\beta}$ 전사 수준은 주사 후 2주부터 유의하게 상승하여 주사 후 4주에 최고 수준에 도달하였으며, 5주 후부터 control 수준으로 감소하였다. $FSH{\beta}$ 전사수준은 주사 후 2주부터 유의하게 상승하여 주사 후 3주에 최고 수준에 도달하였으며, 4주 후부터 감소하여 5주 후에 최소치를 보였다. 유사하게, GnRH-R 전사 수준도 주사 후 2주부터 유의하게 상승하여 주사 후 3주에 최고 수준에 도달하였으며, 5주 후부터 control 수준으로 감소하였다. 본 연구는 EDS 주사에 의해 수컷 흰쥐 뇌하수체 전엽에서의 생식소 자극호르몬 subunit들과 GnRH-R의 발현 변화가 가역적으로 유도될 수 있음을 보여준 것이다. EDS 주사 모델은 수컷 흰쥐에서의 시상하부-뇌하수체 신경내분비 축의 호르몬 조절에 대한 기작을 이해하는데 도움이 될 것이다.

• 한국수정란이식학회지
• /
• 제17권2호
• /
• pp.153-162
• /
• 2002

본 연구에서는 한우의 신속한 증식을 위한 번식기술 개발을 위해 발정이 재귀되지않은 무발정 한우의 번식장애 치료효과와 공태기를 감축하기 위한 난소실질내 PGF／sub 2$\alpha$처치효과를 알아보았다. 1. 번식장애의 감별진단 결과는 검사두수 43두중 둔성발정 또는 발정발견의 잘못이 18두 (41.9%)로 가장 많았고, 난소기능정지 14두 (32.6%), 난포낭종 4두(9.3%), 영구황체 3두 (7.0%), 자궁내막염 2두 (4.7%), 자궁축농증과 황체낭종은 각각 1두(2.3%)로 나타났다. 2. 둔성발정 또는 발정발견의 잘못 18두를 PGF／sub 2$\alpha$／ 25 mg으로치료하여 18두가 발정이 발현되었고 이중 16두 임신되었다. 3. 난소기능정지의 경우는 GnRH 200$\mu\textrm{g}$으로 치료하여 10두중 8두가 발정이 발현되어 이중 7두가 임신이 되었으며, 난포낭종도 역시 CnRH 200$\mu\textrm{g}$으로 치료하여 4두중 3두가 발정이 발현되어서 인공수정후 임신이 되었다. 4. 영구황체 3두와 황체낭종 1두는 각각 PGF／sub 2$\alpha$／ 25 mg으로 치료하여 3두 모두 발정이 발현되어 수정후 임신이 되었다. 5. 자궁내막염 2두는 PGF／sub 2$\alpha$／25mg과 항생제 요법을 병행한 결과 2두 모두 발정이 발현되어서 인공수정후 임신이 되었다. 6.공태기를 줄이기 위한 방법으로 분만 후 20일이 경과한 소에 대해 14일 간격으로 PGF／sub 2$\alpha$/의 난소실질내 투여시 공여동물 23두중 17두에서 임신이 확인되어 74%의 수태율을 보였다. 또한 11일 간격으로 PGF／sub 2$\alpha$／ 를 투여한 군에서는 17두중 16두가 임신되어 94%의 높은 수태율을 보여 공태기를 더 단축할 수 있는 우수한 처리법임을 알 수 있었다.